SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 3
|
records per page:
next > | last >>
|
|
pages:
1
2
3
|
presentations:
1 to
50 of
141
|
WELCOME AND SESSION OVERVIEW: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
(ABSTRACT
1a)
Nicolas Chomont
Université de Montréal, Montreal, Canada
Serena S Spudich
Yale University, New Haven, CT, USA
ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-COV-2
Frank Kirchhoff
Ulm University Medical Center, Ulm, Germany
ADVANCES IN HIV AND SARS-COV-2 IMMUNOLOGY
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC
Jürgen K Rockstroh
Medizinische Universitatsklini, Bonn, Germany
ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Jean-Michel Molina
University of Paris, Paris, France
ADVANCES IN HIV CURE
Katharine J Bar
University of Pennsylvania, Philadelphia, PA, USA
GENERAL Q&A AND SESSION WRAP-UP
Nicolas Chomont
Université de Montréal, Montreal, Canada
Serena S Spudich
Yale University, New Haven, CT, USA
SESSION OVERVIEW
Robert T Schooley
University of California San Diego, La Jolla, CA, USA
David L Thomas
The Johns Hopkins School of Medicine, Baltimore, MD, USA
RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19
(ABSTRACT
11)
Kwok-Yung Yuen
The University of Hong Kong, Hong Kong, Hong Kong
COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS
(ABSTRACT
12)
Sanjay Bhagani
Royal Free Hospital, London, United Kingdom
CRITICAL CARE OF COVID-19
(ABSTRACT
13)
Janhavi Athale
Mayo Clinic Arizona, Phoenix, AZ, USA
QUESTIONS AND ANSWERS WITH THE AUDIENCE
SESSION OVERVIEW
Susan P Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
Richard E Chaisson
The Johns Hopkins University, Baltimore, MD, USA
MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS
(ABSTRACT
9)
Lori Dodd
National Institutes of Health, Bethesda, MD, USA
DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS
(ABSTRACT
10)
Holly Janes
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
LIVE QUESTIONS AND ANSWERS WITH THE AUDIENCE
SESSION OVERVIEW
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff
Ulm University Medical Center, Ulm, Germany
STRUCTURES OF SARS-COV-2 ANTIBODIES INDUCED BY INFECTION AND MRNA VACCINES
(ABSTRACT
5)
Christopher O Barnes
California Institute of Technology, Pasadena, CA, USA
EMERGING CONCEPTS IN HIV-1 RESTRICTION
(ABSTRACT
6)
Edward Campbell
Loyola University Chicago, Maywood, IL, USA
SARS-COV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES
(ABSTRACT
7)
Daniela Weiskopf
La Jolla Institute for Immunology, La Jolla, CA, USA
ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING
(ABSTRACT
8)
Sai Reddy
ETH Zurich, Basel, Switzerland
ADVANCES IN MOLECULAR VIROLOGY
Wesley I. Sundquist
University of Utah, Salt Lake City, UT, USA
ADVANCES IN HIV IMMUNOLOGY AND VACCINES
Richard A. Koup
National Institutes of Health, Bethesda, MD, USA
ISSUES IN MATERNAL, INFANT, AND CHILD HEALTH
Hermione Lyall
Imperial College Healthcare NHS Trust, London, United Kingdom
ADVANCES IN HIV PREVENTION
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
ADVANCES IN HIV CURE
Nicolas Chomont
Université de Montréal, Montreal, QC, Canada
PUTTING ANALYSIS INTO ANALYTICAL TREATMENT INTERRUPTIONS
(ABSTRACT
7)
Lu (Summer) Zheng
Harvard T. H. Chan School of Public Health, Boston, MA, USA
ADVANCING FROM PHASE II TO PHASE III: NAVIGATING THE LAND OF EXPECTATIONS
(ABSTRACT
8)
Patrick PJ Phillips
University of California San Francisco, San Francisco, CA, USA
NONINFERIORITY COMPLEX
(ABSTRACT
9)
Jeffrey Scott Murray
Food and Drug Administration, Silver Spring, MD, USA
INCLUSION OF DIVERSE POPULATIONS IN TRIALS
(ABSTRACT
10)
Mark Harrington
Treatment Action Group, New York, NY, USA
SHAPING VACCINES WITH DNA ORIGAMI
(ABSTRACT
3)
Mark Bathe
Massachusetts Institute of Technology, Cambridge, MA, USA
CONCEPTS IN RESERVOIR MEASUREMENTS
(ABSTRACT
4)
Janet M. Siliciano
The Johns Hopkins University, Baltimore, MD, USA
CHARTING GENOME-WIDE INTEGRATION
(ABSTRACT
5)
Mary F Kearney
National Cancer Institute, Frederick, MD, USA
SINGLE-CELL EPIGENETICS: COLORING IMMUNE CELLS WITH A RICH PALETTE OF HISTONE MARKS
(ABSTRACT
6)
Alex J Kuo
Stanford University, Stanford, CA, USA
WHEN AT THIRD YOU DON'T SUCCEED
(ABSTRACT
11)
David L. Wyles
Denver Health and Hospital Authority, Denver, CO, USA
'A' CASE TO REMEMBER: HEPATITIS A - MANAGING AN OLD VIRUS IN NEW POPULATIONS AT RISK
(ABSTRACT
12)
Darcy Wooten
University of California San Diego, San Diego, CA, USA
HEPATOCELLULAR CARCINOMA
(ABSTRACT
13)
Susanna Naggie
Duke University, Durham, NC, USA
NONALCOHOLIC STEATOHEPATITIS
(ABSTRACT
14)
Kathleen E Corey
Massachusetts General Hospital, Boston, MA, USA
UPDATE ON HIV VIROLOGY
(ABSTRACT
2001)
Paul Bieniasz
The Rockefeller University, New York, NY, USA
UPDATE ON HIV IMMUNOLOGY
(ABSTRACT
2002)
Penelope L. Moore
University of Witwatersrand, Johannesburg, South Africa
UPDATE ON HIV PREVENTION
(ABSTRACT
2003)
Sharon L. Hillier
University of Pittsburgh, Pittsburgh, PA, USA
UPDATE ON TUBERCULOSIS TREATMENT AND PREVENTION
(ABSTRACT
2004)
Constance A. Benson
University of California San Diego, San Diego, CA, USA
UPDATE ON HIV CURE
(ABSTRACT
2005)
Katharine J Bar
University of Pennsylvania, Philadelphia, PA, USA
DISCOVERING THE ART IN SCIENCE (AND MEDICINE): THE HUMAN CONNECTION
(ABSTRACT
2)
Dawn Averitt
The Well Project, Women's Research Initiative on HIV/AIDS, South Strafford, VT, USA
FELLOW TRAVELERS: INTERPRETING THE IMPACT OF THE MICROBIOME IN CLINICAL INTERVENTION
(ABSTRACT
6)
Adam Burgener
Public Health Agency of Canada, Winnipeg, Canada
MISSING U: HANDLING AND AVOIDING MISSING DATA IN CLINICAL TRIALS
(ABSTRACT
7)
Heather Ribaudo
Harvard School of Public Health, Boston, MA, USA
DESIGNING & INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS
(ABSTRACT
8)
David Dunn
University College London, London, United Kingdom
ENGINEERING THE LATENT RESERVOIR
(ABSTRACT
3)
Paula Cannon
University of Southern California, Los Angeles, CA, USA
MORE COLORFUL IMMUNOLOGY: TARGETED ISOLATION OF MONOCLONAL ANTIBODIES
(ABSTRACT
5)
Rosemarie Diana Mason
NIAID, NIH, Bethesda, MD, USA
NOVEL IMAGING APPROACHES TO CHARACTERIZE AND QUANTIFY VIRAL RESERVOIRS
(ABSTRACT
4)
Jacob D Estes
Oregon Health and Sciences University, Beaverton, OR, USA
|
<< first | < prev
page:
of 3
|
records per page:
next > | last >>
|
|
pages:
1
2
3
|
presentations:
1 to
50 of
141
|
